As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
10 Analysts have issued a Kezar Life Sciences Inc forecast:
10 Analysts have issued a Kezar Life Sciences Inc forecast:
| Dec '24 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | - - | 
         
    -
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | -64 -64 | 
         
      
        
        38%
      
      
        
        38%
      
 
        
       | 
      |
| EBIT (Operating Income) EBIT | -65 -65 | 
         
      
        
        38%
      
      
        
        38%
      
 
        
       | 
      |
| Net Profit | -62 -62 | 
         
      
        
        39%
      
      
        
        39%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
| Head office | United States | 
| CEO | Christopher Kirk | 
| Employees | 55 | 
| Founded | 2015 | 
| Website | kezarlifesciences.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


